Northwest Biotherapeutics, Inc. (BST:NBYB)
Germany · Delayed Price · Currency is EUR | Market Cap | 238.12M -26.0% |
| Revenue (ttm) | 1.90M +98.6% |
| Net Income | -34.03M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Open | 0.1400 |
| Previous Close | 0.1400 |
| Day's Range | 0.1400 - 0.1800 |
| 52-Week Range | 0.1000 - 0.3800 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was fou... [Read more]
Financial Performance
In 2025, Northwest Biotherapeutics's revenue was $1.38 million, a decrease of -0.29% compared to the previous year's $1.38 million. Losses were -$61.48 million, -27.84% less than in 2024.
Financial numbers in USD Financial StatementsNews
Northwest Biotherapeutics enters MOU for collaboration with SPIMACO
Northwest Biotherapeutics (NWBO) entered into a non-binding Memorandum of Understanding with the Saudi Pharmaceutical Industries and Medical Appliance Company for a collaboration to bring the Company’...
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA Region BETHESDA, Md., Aug. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (the "Company...
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated BETHESDA, Md., July 8, 2026 /PRNewswire/ -- Northwest Biotherap...
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
BETHESDA, Md., July 2, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor c...
Northwest Biotherapeutics names Annalisa Jenkins as strategic advisor
Northwest Biotherapeutics (NWBO) announced the appointment of Annalisa Jenkins, M.B.B.S., F.R.C.P., as a Strategic Adviser. Dr. Jenkins brings over 25 years of biopharma leadership, spanning global R&...
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
BETHESDA, Md., April 30, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid...
Northwest Biotherapeutics establishes dedicated leukapheresis clinic
Northwest Biotherapeutics (NWBO) is establishing its own dedicated clinic for leukapheresis procedures at The London Welbeck Hospital. The Company is doing so in order to proactively address potential...
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
BETHESDA, Md., April 21, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid...
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
BETHESDA, Md. , Nov. 20, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
BETHESDA, Md. , Oct. 24, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid...
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
BETHESDA, Md. , Aug. 27, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid...
Northwest Biotherapeutics announces passing of general counsel Les Goldman
Northwest Biotherapeutics (NWBO) announced the passing of its Senior Vice President and General Counsel, Les Goldman, due to a stroke. Goldman’s duties are being assumed by other members of the…
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
BETHESDA, Md. , Aug. 18, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumo...
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
BETHESDA, Md. , June 11, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumo...
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
BETHESDA, Md. , Dec. 26, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumo...
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md. , July 3, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company de...
Northwest Biotherapeutics announces exclusive license from Roswell Park
Northwest Biotherapeutics announced that on June 12, 2024 it entered into an exclusive license from Roswell Park Comprehensive Cancer Center for a portfolio of dendritic cell technologies and intellec...
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise BETHESDA, Md. , June 17, 2024 /PRNewswire/ -- Northwest Biotherapeutics (...
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
BETHESDA, Md. , March 21, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, anno...
Northwest Biotherapeutics completes key development work for Flaskworks system
Northwest Biotherapeutics announced that the key development work for the Flaskworks manufacturing system has been completed and an external vendor has been engaged to produce GMP-grade units of the s...
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Accompanied by Broad Patent Coverage BETHESDA, Md. , Feb. 6, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune ther...
Northwest Biotherapeutics submits MAA to MHRA for DCVax-L
Northwest Biotherapeutics announced that a Marketing Authorization Application was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency in the UK for DCVax-L for glioblastoma...
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, Md. , Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing D...
Northwest Biotherapeutics provides update on final preparations for MAA
Northwest Biotherapeutics provided an update about the final preparations for the Marketing Authorization Application that will be submitted to the Medicines and Healthcare Products Regulatory Agency ...
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
BETHESDA, Md. , Nov. 22, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provi...